Where are Cochlear (ASX:COH) shares headed in 2022?

The hearing implant device maker has been a darling of long-term investors for decades. But is the stock too expensive now?

| More on:
An older woman tries to listen by cupping her ear.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) has been a staple for many ASX share portfolios in the past decade.

The hearing device maker has handsomely rewarded its original investors with a 2,350% return, according to Google Finance, and a 13.8% gain over 2021.

However, this year has ended on a sour note, as the share price actually has fallen more than 14% since its August high.

So where to from here? Is it one to buy for 2022?

'Sales have stagnated'

Redpoint Investment Management chief Max Cappetta told The Motley Fool that "revenue growth has faltered" recently for Cochlear.

"Implant sales have stagnated during the COVID pandemic."

Despite sound business prospects, Cappetta reckons that the valuation is "stretched" at the moment.

"Our metrics do point to a resurgence in revenue growth but this seems to be fully priced in at present," he said.

"While there are improving prospects going forward, there also remains the potential for competing products — though we note that the Cochlear's devices remain clear market leaders."

Cochlear shares are dividing the experts

It seems Cochlear shares are polarising analysts.

The Motley Fool's Zach Bristow reported earlier this month that out of 4 major investment houses, one is bearish, one is neutral and two are slightly bullish on the stock.

Goldman Sachs has set a target of $197 a share, which is about a 10% downside from Wednesday morning's price of $218.18.

"The firm says that Cochlear's surgery volumes remain at risk due to their elective nature. It notes that Australian surgery numbers are yet to recover to pre-pandemic volumes," Bristow reported.

"Goldman Sachs recognises these challenges and reckons Cochlear is a sell in a recent note to clients."

Meanwhile Citi is neutral with a $220 target, while Jarden and Macquarie rate Cochlear as a "buy" with targets of $258 and $256 respectively.

According to CMC Markets, 8 of 12 analysts are recommending a "hold" for Cochlear shares as the year winds down.

Motley Fool contributor Tony Yoo owns Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »